Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax - Takeaways - MDSpire

Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax

  • By

  • Fangli Chen

  • Yuanqin Wang

  • Zhen Fu

  • Li Chang

  • Xuewei Jiang

  • Zhizhi Zhang

  • Chongyang Li

  • Ligen Liu

  • Li Yang

  • June 5, 2026

  • 0 min

Share

  • 1

    WNK1 is highly expressed in acute myeloid leukemia (AML), particularly in adverse subtypes like FLT3-ITD mutated AML.

  • 2

    Pharmacological inhibition of WNK1 using WNK463 and WNK11 suppressed AML cell proliferation and induced apoptosis.

  • 3

    WNK1 inhibition downregulated DNA replication pathway genes associated with poor prognosis in AML.

  • 4

    Elevated WNK1 expression correlates with resistance to venetoclax, a drug used in AML treatment.

  • 5

    Combining WNK463 with venetoclax showed synergistic anti-leukemic effects in vitro, enhancing apoptosis.

Original Source(s)

Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax

  • by Fangli Chen, Yuanqin Wang, Zhen Fu, Li Chang, Xuewei Jiang, Zhizhi Zhang, Chongyang Li, Ligen Liu, Li Yang

  • June 5, 2026

Related Content

Mechanisms and biomarkers of immune checkpoint inhibitor-associated myocarditis: from T cell imbalance to multicellular crosstalk

Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study

Case Report: Synaptophysin-positive SMARCA4-deficient undifferentiated thoracic tumour: a diagnostic pitfall with therapeutic implications